A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects

Phase 2

Completed

• Conditions: Obesity
• Interventions: Drug: PYY3-36; Drug: Nasal Placebo; Drug: Placebo Capsule; Drug: Sibutramine

• Registration Number: NCT00537420
• Lead Sponsor: Nastech Pharmaceutical Company, Inc.

Brief Summary

The purpose of this study is to determine the effect of nasal PYY3-36 on weight loss post 24 weeks of treatment.

Detailed Description

This is a multi-center, Phase 2 double-blind, randomized, placebo-controlled trial in healthy obese patients. The primary objective of the study is to evaluate the effect of increasing nasal PYY3-36 dosing on weight loss post 24 weeks of treatment.

Secondary Objectives:

* To evaluate the safety of three nasal PYY3 36 dose groups compared to nasal placebo

* To compare the weight loss post 12 and 24 weeks of treatment for each of the three nasal PYY3 36 dose groups versus the nasal placebo group

* To compare the proportion of patients who lose at least 5% and 10% of the baseline body weight post 12 and 24 weeks of therapy for each of the three nasal PYY3 36 dose groups versus the nasal placebo group

* To compare the weight loss and proportion of patients who lose at least 5% of the baseline body weight post 12 and 24 weeks of treatment with sibutramine versus capsule placebo

* To compare the weight loss and proportion of patients who lose at least 5% of the baseline body weight post 12 and 24 weeks of treatment with nasal placebo versus capsule placebo

* To compare the weight loss and proportion of patients who lose at least 5% of the baseline body weight post 12 and 24 weeks of treatment with sibutramine versus the nasal PYY3 36 dose groups

* To evaluate the effect of 12 and 24 weeks of treatment with nasal PYY3 36 and sibutramine on fasting lipid profile, plasma glucose, insulin, blood pressure and pulse, waist circumference and BMI

* To evaluate the effect of 24 weeks of treatment with nasal PYY3 36 and sibutramine on HbA1c levels

Study Timeline

• Study First Submitted: 2007-09-28
• Study First Submitted QC: 2007-09-28
• Study Start: 2007-10
• Study First Posted: 2007-10-01
• Primary Completion: 2008-07
• Status Verified: 2008-09
• Study Completion: 2008-09
• Last Update Submitted: 2008-09-12
• Last Update Posted: 2008-09-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 551

Inclusion Criteria

• Male or Female patients 18 and 65 years, inclusive;
• BMI 30-43 kg/m2, inclusive;
• In good health, determined by medical history and physical examination, as well as normal 12-lead ECG and vital signs;
• Non-smoker and no use of tobacco or nicotine products for at least 3 months;
• Females will be non-pregnant, non-lactating, and either post-menopausal for at least 1 year, surgically sterile (including tubal ligation, hysterectomy) for at least 3 months, until 30 days following Study Completion be willing to use an approved method of contraception;
• Has normal nasal mucosa.

Exclusion Criteria

• Previous surgical treatment for obesity;
• Serious Medical Condition
• Serious Psychiatric illness
• Organic causes of obesity (e.g. untreated hypothyroidism)
• Type 1 or Type 2 Diabetes;
• Presence of uncontrolled hypertension
• On prohibited concomitant medication

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
3	PYY3-36	Nasal PYY3-36 200 ug
4	PYY3-36	Nasal PYY3-36 400 ug
1	Nasal Placebo	Nasal Placebo
2	Placebo Capsule	Capsule Placebo
5	PYY3-36	Nasal PYY3-36 600 ug
6	Sibutramine	Sibutramine 10 mg

Primary Outcome Measures

Name	Time	Method
To evaluate the effect of increasing nasal PYY3 36 dosing on weight loss post 24 weeks of treatment	24 Weeks

Secondary Outcome Measures

Name	Time	Method
To evaluate the safety of three nasal PYY3 36 dose groups compared to nasal placebo	24 Weeks

Trial Locations

Locations (1)

For additional information regarding investigative sites for this trial, contact 1-425-415-3011; 🇺🇸 Salt Lake City, Utah, United States